BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3040426)

  • 1. The specific opioid kappa-agonist U-50,488H inhibits low Km GTPase.
    Ueda H; Misawa H; Fukushima N; Takagi H
    Eur J Pharmacol; 1987 Jun; 138(1):129-32. PubMed ID: 3040426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of opioid receptors on smooth muscle cells from guinea pig stomach.
    Zhang L; Gu ZF; Pradhan T; Jensen RT; Maton PN
    Am J Physiol; 1992 Mar; 262(3 Pt 1):G461-9. PubMed ID: 1312793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat.
    Yuan CS
    Eur J Pharmacol; 1996 Oct; 314(1-2):27-32. PubMed ID: 8957215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Na+ ions and Gpp(NH)p selectively inhibit agonist interactions at mu- and kappa-opioid receptor sites in rabbit and guinea-pig cerebellum membranes.
    Frances B; Moisand C; Meunier JC
    Eur J Pharmacol; 1985 Nov; 117(2):223-32. PubMed ID: 2866971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mu-, delta- and kappa-agonists on isolated right atria of the rat.
    Micol JA; Laorden ML
    Neuropeptides; 1994 Jun; 26(6):365-70. PubMed ID: 7936123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of mu, delta, and kappa opioid agonists on adenylate cyclase activity.
    De Montis GM; Devoto P; Preti A; Tagliamonte A
    J Neurosci Res; 1987; 17(4):435-9. PubMed ID: 2887665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of opioid receptors on gastric muscle cells by selective receptor protection.
    Grider JR; Makhlouf GM
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G103-7. PubMed ID: 1670978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs.
    Werling LL; Frattali A; Portoghese PS; Takemori AE; Cox BM
    J Pharmacol Exp Ther; 1988 Jul; 246(1):282-6. PubMed ID: 2839666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
    Pugsley MK; Penz WP; Walker MJ; Wong TM
    Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of kappa-opioid receptor mediated tolerance in the guinea-pig ileum by chronic co-administration of dihydropyridines.
    Garaulet JV; Laorden ML; Milanés MV
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Jun; 354(1):72-9. PubMed ID: 8832591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
    Capasso A; Sorrentino L; Pinto A
    Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex.
    Heijna MH; Padt M; Hogenboom F; Portoghese PS; Mulder AH; Schoffelmeer AN
    Eur J Pharmacol; 1990 Jun; 181(3):267-78. PubMed ID: 2166675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prior exposure to morphine on the opioid inhibition of the stimulated release of [3H]norepinephrine from guinea pig cortex slices.
    Werling LL; Brown SR; Cox BM
    NIDA Res Monogr; 1986; 75():587-90. PubMed ID: 2829006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.
    Morris BJ; Millan MJ
    Br J Pharmacol; 1991 Apr; 102(4):883-6. PubMed ID: 1649659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid receptor regulation of the release of norepinephrine in brain.
    Werling LL; Brown SR; Cox BM
    Neuropharmacology; 1987 Jul; 26(7B):987-96. PubMed ID: 2821438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the opioid receptor subtypes mediating the negative inotropic effects of DAMGO, DPDPE and U-50, 488H in isolated human right atria strips.
    Llobell F; Laorden ML
    Neuropeptides; 1995 Aug; 29(2):115-9. PubMed ID: 7477762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.
    Devine DP; Leone P; Pocock D; Wise RA
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1236-46. PubMed ID: 7690399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
    Ukai M; Kameyama T
    Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes.
    Stiene-Martin A; Zhou R; Hauser KF
    Glia; 1998 Mar; 22(3):249-59. PubMed ID: 9482211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.